PATINA’s 44‑Month Shockwave

Dr. Mouabbi is still in awe of PATINA’s headline: a median PFS of 44 months after adding palbociclib to maintenance T-DXd plus endocrine therapy in HER2‑positive, ER‑positive metastatic breast cancer. Dr. Rimawi explains why the result felt like it came “out of left field.” The secret is in the sauce of randomization timing. The take‑home: potent maintenance without additional chemotherapy can eclipse ADC benchmarks, prompting a fresh look at where CDK4/6 inhibitors, endocrine therapy, and future ADCs might peacefully coexist in first‑line sequencing.